158681-13-1

158681-13-1 structure

Name: SR 141716A
Chemical Name: Rimonabant Hydrochloride
CAS Number: 158681-13-1
Molecular Formula: C₂₂H₂₂Cl₄N₄O
Molecular Weight: 500.248
Catalog: Signaling Pathways Autophagy Autophagy
Create Date: 2018-09-16 10:12:28
Modify Date: 2026-07-23 15:00:35
Rimonabant hydrochloride is a cannabinoid receptor (CB) antagonist which binds selectively to CB1 with a Ki of 2 nM.

Name	Rimonabant Hydrochloride
Synonyms	Rimonabant hydrochloride###Rimonabant 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide hydrochloride (1:1) Rimonabant HCl - Bio-X 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide hydrochloride (1:1) 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-1-piperidinyl-1h-pyrazole-3-cboxamide monohydrochloride N-(piperidine-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-Methyl-1H-pyrazole-3-cboxaMide hydrochloride RiMonabant(SR141716A) Rimonabant hydrochloride 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-cboxamide monohydrochloride RIMONABANT HYDROCHLORIDE ACOMPLIA Acomplia, SR141716 RimonabantConsultedStandd 5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-Methyl-1H-pyrazole Rimonabant HCl (SR141716) MFCD04034714 Rimonabant hydrochloride ISO 9001：2015 REACH N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-cboxamide hydrochloride Rimonabant(Acomplia) RiMonabant-d10 HCl RIMONABANT HCL 1H-Pyrazole-3-cboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-, hydrochloride (1:1) RiMonabant hydrochloride(SR141716A) Rimonabant HydrochlorideQ: What is Rimonabant Hydrochloride Q: What is the CAS Number of Rimonabant Hydrochloride Q: What is the storage condition of Rimonabant Hydrochloride Q: What e the applications of Rimonabant Hydrochloride 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-Methyl-N-(piperidin-1-yl)-1H-pyrazole-3-cboxaMide SR 151716A Rimonabant hydrochloride Solution in Methanol, 100μg/mL SR 141716 hydrochloride Urapidil Impurity 9-d4 Rimonabant hydrochloride, 10 mM in DMSO 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-Methyl-N-1-piperidinyl Rimonabant Hcl(SR141716A) 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-cboxamide hydrochloride Minoxidil Base & Sulfate 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-Methyl-N-(piperidin-1-yl)-1H-pyrazole-3-cboxaMide hydrochloride N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-cboxamide HCl Rimonabant ACOMPLIA (RIMONABANT SR 141716A; SR 151716A Rimonabant (Hydrochloride) 1H-Pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-, hydrochloride (1:1) Rimonabant hydrochloride 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide,hydrochloride

Description	Rimonabant hydrochloride is a cannabinoid receptor (CB) antagonist which binds selectively to CB1 with a Ki of 2 nM.
Related Catalog	Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> GPCR/G Protein >> Cannabinoid Receptor Research Areas >> Metabolic Disease
Target	Ki: 2 nM (CB1 receptor)[1]
In Vitro	Rimonabant hydrochloride (SR 141716A) binds selectively to central cannabinoid receptors (CB1) with high affinity (Ki=2 nM), and blocks the inhibitory effects of cannabinoid receptor agonists in the mouse vas deferens, dopamine-stimulated adenylyl cyclase and WIN 55212-stimulated GTPγS binding[1]. Rimonabant dose-dependently inhibited CO synthesis in Raw 264.7 macrophages, with 1 µM producing a significant (~40%) decrease compared to untreated controls and concentrations ≥ 5 µM producing near complete inhibition. A small, but significant, reduction of TG and DG synthesis is also observed with Rimonabant at concentrations ≥ 10 µM. Inhibition of CO synthesis in Raw 264.7 macrophages by Rimonabant (IC50 value 2.9±0.38 µM) is very similar to that of AM251 and SR144528 (IC50 value 2.6±0.26 µM and 2.5±0.32 µM, respectively), two related compounds previously demonstrated to be potent ACAT inhibitors. Mouse peritoneal macrophages also displayed significantly reduced CO synthesis in response to Rimonabant treatment. Rimonabant at concentrations ≥ 1 µM significantly inhibits CO synthesis in CHO-ACAT1 and CHO-ACAT2 cells in a concentration-dependent manner with similar efficiency (IC50s of 1.5±1.2 µM and 2.2±1.1 µM, respectively)[2].
In Vivo	Pretreatment with Rimonabant hydrochloride (SR 141716A) blocks the antinociceptive, discriminative stimulus, memory impairing and hypolocomotor effects produced by Δ-9-THC. SR 141716A also precipitates a withdrawal syndrome in rats treated chronically with Δ-9-THC[1]. Pretreatment of mice with 0.1 mg/kg of WIN 55212-2 is effective in increasing the CPP induced by MDMA , while 1 mg/kg of Rimonabant specifically blocks CB1 receptors and does not act as an inverse agonist[3].
Kinase Assay	Raw 264.7 cells (2×106/well) in 12-well plates are rinsed with PBS and refed culture media supplemented with varying amounts of Rimonabant 1h prior to supplementation with 7-ketocholesterol (7KC). All wells are adjusted to receive equal amounts of vehicle. Following a 16 h incubation, caspase-3 and caspase 3-like activity is determined[2].
Animal Admin	Mice[3] A total of 250 male mice of the OF1 strain (21 days of age) are used. Animals are injected i.p. with cocaine hydrochloride, WIN 55212-2, or Rimonabant (SR 141716A) in a volume of 0.01 mL/g. Control groups are injected with the physiological saline used to dissolve cocaine (NaCl 0.9%) or with Tween-80, which is used to dissolve WIN 55212-2 and Rimonabant (0.01%, 0.01 mL of Tween dissolved in 100 mL of saline). The doses of cocaine administered are selected on the basis of previous studies showing that 1 mg/kg is a subthreshold dose for inducing CPP in naïve mice, while 6 mg/kg is effective in inducing CPP acquisition but not in producing reinstatement after extinction of CPP. Similarly, the doses of cannabinoid drugs administered are selected on the basis of previous studies on the effects of WIN 55212-2 in the CPP paradigm and on the effects of cannabinoid pretreatment on the CPP induced by other drugs of abuse.
References	[1]. Vivian JA, et al. Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A. J Pharmacol Exp Ther. 1998 Aug;286(2):697-703. [2]. Netherland C, et al. Rimonabant is a dual inhibitor of acyl CoA:cholesterol acyltransferases 1 and 2. Biochem Biophys Res Commun. 2010 Aug 6;398(4):671-6. [3]. Rodríguez-Arias M, et al. Effects of Cannabinoid Exposure during Adolescence on the Conditioned Rewarding Effects of WIN 55212-2 and Cocaine in Mice: Influence of the Novelty-Seeking Trait. Neural Plast. 2016;2016:6481862.

Boiling Point	627.6ºC at 760 mmHg
Melting Point	230-240ºC
Molecular Formula	C₂₂H₂₂Cl₄N₄O
Molecular Weight	500.248
Flash Point	333.3ºC
Exact Mass	498.054779
PSA	50.16000
LogP	7.06940
Storage condition	-20°C Freezer

Symbol	GHS06
Signal Word	Danger
Hazard Statements	H301-H319
Precautionary Statements	P301 + P310-P305 + P351 + P338
Hazard Codes	T,Xi
Risk Phrases	25-36
Safety Phrases	26-45
RIDADR	UN 2811 6.1 / PGIII

2213-43-6

168273-05-0

158681-13-1

Literature: WO2008/32330 A2, ; Page/Page column 7 ;

168273-06-1

158681-13-1

Literature: WO2006/87732 A1, ; Page/Page column 6 ;

6285-05-8

158681-13-1

Literature: Organic Preparations and Procedures International, , vol. 44, # 2 p. 164 - 168

5446-18-4

158681-13-1

Literature: Organic Preparations and Procedures International, , vol. 44, # 2 p. 164 - 168

Precursor 5
2213-43-6 168273-05-0 168273-06-1 6285-05-8
5446-18-4
DownStream 1
168273-06-1

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

1806815-25-7	1805170-64-2
1805243-38-2	1806816-27-2
1804637-39-5	1806810-39-8
1805983-24-7	1806917-27-0
1805017-39-3	1805256-27-2